First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.
A study found that young non-smokers with healthier diets had higher rates of lung cancer, raising questions about whether pesticide exposure from conventionally grown produce could play a role.
New research demonstrates that RNA-based testing can improve detection of MET exon 14 skipping mutations in lung cancer patients, while circulating tumor DNA (ctDNA) testing is increasingly being adopted for early cancer detection and treatment monitoring across oncology.
Ivonescimab, an experimental drug combining two immunotherapy mechanisms, reduced the risk of death by 34% compared to standard immunotherapy in patients with advanced squamous non-small cell lung cancer in a closely watched Chinese trial. The drug helped patients live 15% longer than BeOne Medicines' Tevimbra.
